HomeFull speed ahead. Keep track of advancements in every frontier

TheTechno Optimist.

Fosigotifator (ABBV-CLS-7262)Calico—Fosigotifator (ABBV-CLS-7262)Calico—

Calico

Aging biology, stress-pathway drug, AbbVie

USAlphabet-ownedest. 2013calicolabs.com (opens calicolabs.com)Checked 25 Sep

The brief

Analyst view
  • Fosigotifator failed in an ALS trial (Jan 2025) but won FDA Breakthrough status for a rare brain disease in Jun 2026.
  • AbbVie ended the joint R&D partnership, begun in 2014 and extended in 2021, in Nov 2025 after investing about $1.75B.
Programs

Calico, one program

Updated 23 Jun 2026
Fosigotifator (ABBV-CLS-7262)A pill that switches off a stuck stress alarm in cells (the integrated stress response), letting them make proteins normally again. The alarm is linked to brain disease and aging.PilotNextFinish rare-disease trialUpdated 23 Jun 2026View program →
Research · Proto · Pilot · Deploy · Scaling

Research & demos

1 item

Upcoming catalysts

Company-wide
  • Nov2027Vanishing white matter study (NCT05757141) primary completion, per trial registryFosigotifator (ABBV-CLS-7262)by ~14 mo

Peers

Anti-aging drugs · 3

Company & funding

Parent
Alphabet
HQ
US
Founded
2013

Partners & customers

1 partner

People

Key people
Primer